Home › Wilms Tumor › District of Columbia
Wilms Tumor clinical trials in District of Columbia
7 studies for Wilms Tumor are looking for participants at sites in District of Columbia.
Cities in District of Columbia
Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor
- Children's National Medical Center, Washington D.C.
RecruitingPhase 2
Ages 12 to 39 · All sexes · Updated Sep 29, 2026 · NCT04616560Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Children's National Medical Center, Washington D.C.
RecruitingPhase 1/2
12 Months – 30 Years · All sexes · Updated Aug 25, 2026 · NCT04851119A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
- MedStar Georgetown University Hospital, Washington D.C.
- Children's National Medical Center, Washington D.C.
RecruitingPhase 2
Up to age 30 · All sexes · Updated Aug 25, 2026 · NCT04322318Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)
- Children's National Hospital, Washington D.C.
- Childrens National Hospital, Washington D.C.
RecruitingPhase 1
Ages 1 to 23 · All sexes · Updated Aug 13, 2026 · NCT07172958Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
- Children's National Medical Center, Washington D.C.
RecruitingPhase 1/2
12 Months – 30 Years · All sexes · Updated May 19, 2026 · NCT04901702A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
- Children's National Hospital (Data Collection Only), Washington D.C.
RecruitingPhase 2
12 Months · All sexes · Updated May 6, 2026 · NCT05985161A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
- Children's National Medical Center, Washington D.C.
RecruitingPhase 2
18 Months – 40 Years · All sexes · Updated Aug 12, 2025 · NCT05135975From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.